drugset / Trial / NCT00713518
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-11
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 1 mg | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 3 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |